Sanofi announced that it will be "realigning" its U.S. diabetes and cardiovascular business, according to an article in BioPharmaDIVE. The company said there would be a staff reduction of about 20 percent, including sales force and business support functions for that division.
Sanofi said it will provide "separation packages, which include severance pay, health benefits and outplacement services" and that employees have the opportunity to apply for other jobs within the company, the story said.
The realignment stems from its blockbuster insulin Lantus (insulin glargine), which lost patent exclusivity in 2015, faces a new threat from the launch of Eli Lilly's biosimilar Basaglar.
Read the full story